Aastrom Biosciences (ASTM)
Aastrom is developing a personalized, or patient specific, stem cell therapy for the treatment of critical limb ischemia. Patients with chronic CLI have obstructed arteries and reduced blood flow in the arms and legs, which can lead to open wounds and amputation in the most severe cases.Mixed results from a phase II study and delays in negotiating the design of twin phase III studies with the U.S. Food and Drug Administration have weighed on Aastroms' stock price. Aastrom is a long-term story but last week's FDA approval of Fibrocell Sciences' (FCSC) personalized cellular therapy for face wrinkles demonstrates that regulators are ready and willing to tackle stem cell therapeutics.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts